Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D) – SCNow

Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D)  SCNow

NEW ALBANY, Ohio–(BUSINESS WIRE)–Jan 2, 2019–Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) …

Source: Genome Sequencing